-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
▎Clinical problems:
Patients with rectal adenocarcinoma of T2-T3ab, N0, M0; A total of 173 people were included;
(2) Patients were randomly assigned to CRT-TME or TME groups (CRT-TEM: 86, TME: 87), and 11 people were excluded after randomization (CRT-TEM: 5, TME: 6); In the end, 81 people in the CRT-TEM group and TME group were in the TME group;
(3) CRT tolerance and its adverse reactions, surgical complications (Clavien-Dindo and comprehensive complication index classification) and pathological outcomes (complete response in CRT-TEM group) of the included patients in the two groups were recorded;
(4) Patients participate in follow-up control to understand local and systemic recurrence
.
▎Key findings:
(1) The patient did not die after CRT;
(2) In the CRT-TEM group, one patient stopped CRT treatment, accounting for 1/81 (1.
2%);
(3) The incidence of CRT was 29.
6%;
(4) the postoperative incidence in the CRT-TME group was 17/82 (20.
7%), and the TME group was 41/81 (50.
6%) (p<0.
001, 95% CI 43.
9-15.
9);</b127> The assistant for to the and click the column
1 minute a day, give you professional "talking points" in the tumor circle! (If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain)
1
Ann Oncol: Preoperative chemoradiotherapy combined with transanal endoscopic minimally invasive surgery for rectal cancer patients has a better effect
▎Clinical problems:
Total mesenterectomy (TME) is the standard treatment
for T2-T3ab, N0, M0 rectal cancer.
Preliminary studies have shown that the combination of preoperative chemoradiotherapy (CRT) and transanal endoscopic minimally invasive surgery (TEM) reduces the rate of
local recurrence.
However, the advantages and disadvantages of CRT-TEM and TME therapy in terms of local recurrence rates are unclear
.
A randomized controlled trial from Ann Oncol showed that for T2-T3ab, N0, M0 rectal cancer, CRT-TEM treatment was superior to TME treatment
in pathological complete response rates (CRR), CRT adherence, and postoperative complications and hospitalizations.
Patients with rectal adenocarcinoma of T2-T3ab, N0, M0; A total of 173 people were included;
(2) Patients were randomly assigned to CRT-TME or TME groups (CRT-TEM: 86, TME: 87), and 11 people were excluded after randomization (CRT-TEM: 5, TME: 6); In the end, 81 people in the CRT-TEM group and TME group were in the TME group;
(3) CRT tolerance and its adverse reactions, surgical complications (Clavien-Dindo and comprehensive complication index classification) and pathological outcomes (complete response in CRT-TEM group) of the included patients in the two groups were recorded;
(4) Patients participate in follow-up control to understand local and systemic recurrence
.
▎Key findings:
(1) The patient did not die after CRT;
(2) In the CRT-TEM group, one patient stopped CRT treatment, accounting for 1/81 (1.
2%);
(3) The incidence of CRT was 29.
6%;
(4) the postoperative incidence in the CRT-TME group was 17/82 (20.
7%), and the TME group was 41/81 (50.
6%) (p<0.
001, 95% CI 43.
9-15.
9);</b127> The assistant for to the and click the column
4.
Find the "top journal essentials" in clinical medication
Follow the column
Subscribe to the column and read a new top magazine every day!
Download the Doctor Station App and subscribe anytime, anywhere~
